Essential Genes to Consider in Epstein-Barr Virus-Associated Gastric Cancer: A Systematic Review

Ana S. Armenta-Quiroga 1, Raheela Khalid 1, Paramvijay Singh Dhall 2, Jian Garcia 1, Anusha Bapatla 3, Arunima Kaul 3, Safeera Khan 1

1. Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 2. Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA

Corresponding author: Ana S. Armenta-Quiroga, anasofia.armentaq@gmail.com

Abstract

Gastric cancer (GC) is a prevalent malignancy worldwide; the Epstein-Barr Virus (EBV) also affects many people worldwide. An important association has been seen in these two diseases that could explain causality and a possible viral etiology of GC as has been seen with Helicobacter pylori. This study aims to identify genes expressed in malignant cells that are infected with EBV and see if one could be more oncogenic than the other. We conducted a systematic review based on the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines. We had 29 observational studies after inclusion/exclusion criteria and quality assessment for every single study. A total of 1022 patients were evaluated for different types of genes in 29 papers. It was demonstrated that the most expressed genes or the gene most involved were genes that are seen in Epstein-Barr virus-associated gastric cancer (EBVaGC) as latent genes of the EBV-infected cells, which are found in tumor cells. The genes that were mostly involved were LMP2, BNLF2a, and the absence of LMP1 that lead to the expression of BARF1, among other genes. These studies were made on mostly Asian populations, so it is still unknown if these genes involved have a geographical association more than an EBV and GC association.

Introduction And Background

Epstein-Barr Virus-associated gastric cancer (EBVaGC) is 10% of all gastric carcinomas, representing the fifth-most common cancer worldwide and the third-most deadly cancer [1, 2].

Gastric cancer is a multifactorial disease that is associated with several risk factors that could contribute to the cause of this disease. This cancer has been linked to the presence of Helicobacter pylori, which suggests an infectious etiology related to this malignancy [1]. There are variations in incidence between countries, age, and sex. That is why it is also believed that because it’s a multifactorial disease, the genetic part plays an essential role in developing gastric cancer [2, 3].

On the other hand, the Epstein-Barr virus is characterized by its double-stranded DNA and belonging to the herpes virus family [4]. It is a virus that has infected approximately 90% of adult individuals and is known for being self-limiting. In a few cases, it has been distinguished by developing malignancy of lymphoid and epithelial origin [5, 6]. This virus can remain latent in the B lymphocytes of the infected individual [4].

EBVaGC has important molecular characteristics because of the expression of different genes and its epigenetic profile [7]. It is believed that the Epstein-Barr virus could be another infectious agent that contributes to the transformation of gastric cells into malignant cells due to different cellular processes and signaling pathways [8].

As mentioned, an infectious etiology has been suggested. The mechanism of Helicobacter pylori and gastric cancer is very well known; however, another infectious agent has been identified as significantly associated with this type of cancer. The specific variables of the Epstein-Barr virus that cause this cancer and the expressed genes that are involved are still not well understood, and it is still unknown if any of these is more oncogenic than the others.

Today, the different genes associated with gastric cancer are still being investigated. Likewise, the mechanisms and pathways that produce overexpression or loss are studied [9, 10]. There is already a bit of information about new therapeutic approaches considering the evidence on the subject [11].

This study aims to search for the specific genes of the Epstein-Barr virus that are expressed in gastric cancer and determine if any of these is more oncogenic than the other. Studying this is very useful since these
genes can eventually serve as a target for the specific treatment of the disease.

**Review**

**Methods**

**Study Design**

We conducted a systematic review based on the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines.

**Eligibility Criteria**

We selected all observational studies related to this topic, Epstein-Barr virus, gene expression, and gastric cancer, for the last 10 years. We included all types of studies found in full text and done in humans, excluding all those studies in animals. The articles included were in the English and Spanish languages. Finally, gray literature and narrative review were excluded.

**Databases and Search Methods**

We used the PubMed database to search for relevant studies for our data collection. This search was done between the 9th and the 13th of July 2020. For this, we used the medical subject headings (MeSH) Keyword. First, we searched 'Stomach Neoplasm,' "Herpes 4, Human" and "Epstein-Barr Virus Nuclear Antigens," which showed 110,438, 15,075, and 5,377 results, respectively. We then decided to use a MeSH Strategy instead of a more effective search of articles related to the topic. The combined keywords we used in this strategy were the following: "Stomach Neoplasms/microbiology"[MeSH] AND "Herpesvirus 4, Human"[MeSH] AND "Viral Matrix Proteins"[MeSH], "Stomach Neoplasms/microbiology"[MeSH] AND "Epstein-Barr Virus Nuclear Antigens"[MeSH] and "Stomach Neoplasms/microbiology"[MeSH] AND "Herpesvirus 4, Human/pathogenicity"[MeSH] AND "Proteins"[MeSH].

**Study Selection**

The eligibility process is shown in Table 1, which represents the evolution of the use of inclusion/exclusion criteria and screening process to select studies.

| MeSH Strategy                                                                 | Database | Before Inclusion/exclusion criteria | After Inclusion/exclusion criteria | After the screening process |
|--------------------------------------------------------------------------------|----------|-------------------------------------|-----------------------------------|----------------------------|
| "Stomach Neoplasms/microbiology"[MeSH] AND "Herpesvirus 4, Human"[MeSH] AND "Viral Matrix Proteins"[MeSH] | PubMed   | 52                                  | 12                                | 11                         |
| "Stomach Neoplasms/microbiology"[MeSH] AND "Epstein-Barr Virus Nuclear Antigens"[MeSH] | PubMed   | 42                                  | 14                                | 10                         |
| "Stomach Neoplasms/microbiology"[MeSH] AND "Herpesvirus 4, Human/pathogenicity"[MeSH] AND "Proteins"[MeSH] | PubMed   | 40                                  | 13                                | 8                          |

**TABLE 1: MeSH strategy used in the literature search**

Inclusion/exclusion criteria and screening process for article eligibility.

After the first search, we had 134 articles, and once we applied the inclusion-exclusion criteria, we had 40. We excluded all the articles that were duplicated and not relevant to the topic of the screening process. We excluded four articles because they were not pertinent and seven because of duplicates in the search giving us 29 papers.

**Risk of Bias and Quality Assessment**

To reduce the risk of bias, we did a quality assessment of every paper to avoid this risk. We used the New-Castle–Ottawa questionnaire to assess all of the observational studies.

**Results**

The search results focused on observational studies that discussed specific genes that were expressed in EBVaGC. This was done to point out genes present in Epstein-Barr virus and see if any is more oncogenic than the others, especially for the evolution of gastric cancer. After we used the inclusion/exclusion criteria,
29 articles were obtained from which the data were abstracted. Figure 1 shows the evolution of the search.

From the 29 observational studies, 15 cohort studies and 14 cases and controls were obtained. A quality assessment was carried out of these studies, getting favorable results. Of the 29 papers, we evaluated 1022 patients for the expression of a different gene. As shown in Table 2, all the included studies are mentioned, the type of study of each one, year of publication, country, and the genes studied by paper. These articles include samples from countries such as China, Japan, Korea, Thailand, United States, India, Portugal, Iran, Canada, and Zambia. It is worth highlighting the fact that most of the population studied in these articles is Asian.
## TABLE 2: Qualitative aspects of the included studies

At first glance the article summary demonstrates that the genes that are most seen in EBVaGC are the latent genes of the EBV-infected cells, which are found in tumor cells. In Figure 2, we see the comparison made between the number of evaluated patients per gene and the number of patients who express that gene. The most expressed genes are shown on the right side.
FIGURE 2: Comparison of the number of patients evaluated by each gene and the total number of patients who expressed the said gene.

Discussion

Genes Expressed in Latently Infected Cells

Most of the EBVaGC patients studied were sought for association with genes expressed in latently infected cells; infected cells which showed a higher detection of EBER, EBNA1, EBNA3A, and LMP2. As shown in Figure 2, most patients express the Epstein-Barr virus encoded-small RNAs (EBERs), however this only means that the virus is present in the malignant cells since it represents the non-coding RNA associated with Epstein-Barr virus. It is essential to recognize this fact because it means that the presence of the virus in gastric cells can be an important factor in the development of malignancy [27].

An additional possible oncogenic expression may include the latent membrane protein 2 (LMP2) expression that has been seen to induce hypermethylation of various factors through up-regulation that has enormous carcinogenic potential. Ribeiro et al. state that LMP2 causes up-regulation of DNMT1 and phosphorylation of STAT3 [22]. Wang et al. mention the hypermethylation of AQP3, and Zhao et al. talk about the up-regulation of DNMT3b, which causes hypermethylation of almost 886 genes that are involved in cancer-related pathways [10, 36]. It is essential to recognize that the presence of LMP2 leads to many different pathways with the potential to develop a malignancy. The fact that it is present in so many patients suggests that it is an essential factor that could cause EBVaGC.

Studies by Wang et al. and Han et al. have shown that PY and ITAMs regions are highly conserved in LMP2, suggesting that they play an essential role in the viral infection. These regions are considered crucial for possible treatment options targeted LMP2 directed explicitly to these regions. Epitope mutations still have to be considered, this will make target immunotherapy more challenging, but it is an excellent place to start [15,30].

Regarding LMP1, it has been determined that it has an oncogenic activity. According to Wanvimonsuk et al., it has been noted that it is expressed in a decreased way or absent in this disease [28,32]. However, according to Wang et al., the presence of LMP1 leads to the expression of BARF1, which might also play a role in the development of malignant cells [28].

Finally, the Epstein-Barr virus nuclear antigen (EBNA) expression shows that it is more common in most patients to express EBNA1 and EBNA3C. Moreover, EBNA1 has been seen to have an essential role in malignancy development. Armero et al. mention that it interacts with cellular splicing factors, and Nakayama et al. say that it induces the expression of PD-L1, which plays a vital role in diseases such as cancer [7,21]. This suggests that it is a possible factor that can contribute as a cause of EBVaGC [21]. However, it was seen by Chen et al. that polymorphisms can have geographic-associated polymorphisms rather than tumor-specific mutations, which is why it is essential to do more studies in different patients to determine if this is true [13]. Likewise, EBNA3C is known to be a geographic-associated polymorphism in China [33].

Other Expressed Genes

Other expressed genes that were seen with greater frequency were BNLF2a, PD-L1, GPC4, and BARF. BNLF2a is a gene expressed in EBV with the function of viral evasion against HLA I, giving T-cell immunity. In some studies, it has a protective role in latently infected tumor cells [26]. It was seen that type A, BNLFaA, is dominant in a study done in the Chinese population, and B1, BNLF2aB1, is geographically restricted to this population. BNLFa expression in the patients seen in Liu et al. study demonstrated a highly conserved gene
that gives us another option for targeted immunotherapy. However, it is essential to consider that more studies should be made to see if it is highly conserved in patients from other countries [23].

The presence of PD-L1 has been detected in patients’ tumor cells in some studies; however, it’s common to see the expression of this gene in many different types of cancer. It is not a specific gene for EBVaGC, but the overexpression of PD-L1 does regulate some signaling pathways with malignant potential [14,21]. Even though it’s not specific for this malignancy, it is an immunotherapy option for many cancers [14]. A recent paper by Sundar et al. studies LMP1 expression. Even though LMP1 expression is higher in EBVaGC, it states that EBVaGC with lower expression of PD-L1 in tumor cells leads to the worst prognosis, which is also an excellent point to consider [27].

There is not much information about GPC4 expression. Still, it was seen in Zhao et al. study that in a Chinese population, there is a polymorphism of this gene that may represent a risk factor given by the susceptibility associated with this polymorphism to develop EBVaGC [2]. Nevertheless, we come back to the same issue; it is unknown if this polymorphism is of the Chinese population only and if the susceptibility changes depending on the population.

Finally, BARF1 is another crucial factor to consider. This is because in the absence of LMP1, as it was already mentioned, BARF1 is expressed, causing its protein to promote the proliferation of EBV-infected malignant gastric cells. It does this through some pathways that may have essential functions in gastric cancer tumorigenesis. In the papers that studied the expression of this gene, in most cases, the expression of BARF1 was found. Then again, more studies are needed to determine this factor as a possible cause [12,28].

The rest of the genes mentioned before may play a role in malignancy development; however, this role is not found in most cases. This means that even though they are essential, they are not the priority since it could not help a general population, only specific patients. Perhaps when more is known about EBVaGC and the most common genes involved, it will be useful to research these genes.

This study had limitations mostly since it is very little published evidence on the subject. This could lead to publication bias; however, the data abstraction and review were done from a complete database available at the time. Another limitation is that most of the patients studied are from the Asian population; however, there could be variations between populations that we do not see or dominant polymorphisms in the different populations that predominate in the Asia population and differ from those of the rest. The lack of information only prompts more studies to be carried out in other populations.

Conclusions

Different genes were studied and identified in patients with EBVaGC. We can conclude that latent EBV genes were mostly expressed in malignant cells such as LMP2, BNLF2a, and the absence of LMP1 showed that lead to the expression of BARF1, among other genes. It is important to emphasize that most of the patients are Asian, so it is unknown if these genes could be associated with this disease in this population only. It would be recommended in the future to carry out more studies in patients from different countries to determine whether these genes are expressed in EBVaGC of all patients or only of this population.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that there are no financial relationships with any organizations that might have an interest in the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Morales-Sanchez A, Fuentes-Panana EM: Epstein-Barr virus-associated gastric cancer and potential mechanisms of oncogenesis. Curr Cancer Drug Targets. 2017, 17:534-554. 10.2174/1568009616666160926124923
2. Zhao D, Liu S, Sun L, et al.: Glypican-4 gene polymorphism (rs1048569) and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma. Virus Res. 2016, 220:52-56. 10.1016/j.virusres.2016.04.005
3. Rymbai ML, Ramalingam VV, Samarasan I, et al.: Frequency of Epstein-Barr Virus infection as detected by messenger RNA for EBNA 1 in histologically proven gastric adenocarcinoma in patients presenting to a tertiary care center in South India. Indian J Med Microbiol. 2015, 33:369-373. 10.4103/0255-0857.158556
4. Nishikawa J, Iizasa H, Yoshiyama H, et al.: The role of epigenetic regulation in Epstein-Barr virus-associated gastric cancer. Int J Mol Sci. 2017, 18:1606. 10.3390/ijms18081606
5. Tsai MH, Lin X, Shumilov A, et al.: The biological properties of different Epstein-Barr Virus strains explain their association with various types of cancers. Oncotarget. 2017, 8:10238-10254. 10.18632/oncotarget.14380
6. Lee HG, Kim H, Kim EI, et al.: Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation. Oncotarget. 2015, 6:51018-51029. 10.18632/oncotarget.5041

7. Armero VES, Tremblay MP, Aliaire A, et al.: Transcriptome-wide analysis of alternative RNA splicing events in Epstein-Barr virus-associated gastric carcinomas. PLoS ONE. 2017, 12:017680. 10.1371/journal.pone.017680

8. Kang BW, Baek DW, Kang H, Baek JL, Kim JG: Novel therapeutic approaches for Epstein-Barr virus-associated gastric cancer. Anticancer Res. 2019, 39:6973-6979. 10.21873/anticancer.13555

9. Wang J, Zheng X, Qin Z, et al.: Epstein-Barr virus miR-BART3-5p promotes tumorigenesis by regulating the senescence pathway in gastric cancer. J Biol Chem. 2019, 294:4854-4866. 10.1074/jbc.A118.006853

10. Wang J, Liu W, Zhang X, Zhang Y, Xiao H, Luo B: LMP2A induces DNA methylation and expression repression of AQP3 in EBV-associated gastric carcinoma. Virology. 2019, 534:87-95. 10.1016/j.virol.2019.06.006

11. Kim YB, Ahn JM, Bae WJ, Sung CO, Lee D: Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int J Cancer. 2019, 145:916-926. 10.1002/ijc.32140

12. Chang MS, Kim DH, Roh IK, et al.: Epstein-Barr virus-encoded BARF1 promotes proliferation of gastric carcinoma cells through regulation of NF-κB. J Virol. 2015, 87:10515-10525. 10.1128/JVI.00955-15

13. Chen JN, Zhang NN, Jiang Y, et al.: Variations of Epstein-Barr virus nuclear antigens 1 in Epstein-Barr virus-associated gastric carcinomas from Guangzhou, southern China. PLoS ONE. 2012, 7:50084. 10.1371/journal.pone.0050084

14. Cho CJ, Kang HI, Ryu YM, et al.: Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. Gastric Cancer. 2018, 21:925-935. 10.1007/s10120-018-0820-3

15. Han J, Chen JN, Zhang ZG, Li HG, Ding YG, Du H, Shao CK: Sequence variations of latent membrane protein 2A in Epstein-Barr virus-associated gastric carcinomas from Southern China. PLoS ONE. 2012, 7:54276. 10.1371/journal.pone.0054276

16. He D, Zhang YW, Zhang NN, Zhou L, Chen JN, Jiang Y, Shao CK: Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas. Med Oncol. 2015, 32:92. 10.1007/s12052-015-0525-y

17. Kayama V, Morone M, Asombang AW, Zayombo K, Kelly P: Serological response to Epstein-Barr virus early antigen is associated with gastric cancer and human immunodeficiency virus infection in Zambian adults: a case-control study. Pan Afr Med J. 2016, 25:45. 10.11604/pamj.2016.25.45.8503

18. Kosari-Monfared M, Nikkhah N, Fattahi S, et al.: CTNNBIPI downregulation is associated with tumor grade and viral infections in adenocarcinoma. J Cell Physiol. 2019, 234:2895-2904. 10.1002/jcp.27106

19. Luo B, Liu M, Chao Y, Wang Y, Jing Y, Sun Z: Characterization of Epstein-Barr virus gp350/220 gene variants in virus isolates from gastric carcinoma and nasopharyngeal carcinoma. Arch Virol. 2012, 157:207-216. 10.1007/s00705-011-1148-z

20. Moon JW, Kong SK, Kim BS, et al.: IFNγ induces PD-L1 overexpression by Jak2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma. Sci Rep. 2017, 7:17810. 10.1038/s41598-017-18132-0

21. Nakayama A, Abe H, Kunita A, et al.: Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr virus-associated gastric carcinoma. PLoS ONE. 2019, 14:0211358. 10.1371/journal.pone.0211358

22. Ribeiro J, Oliveira A, Malta M, et al.: Clinical and pathological characterization of Epstein-Barr virus-associated gastric carcinomas in Portugal. World J Gastroenterol. 2017, 23:7292-7292. 10.3748/wjg.v23.i40.7292

23. Liu S, Wang X, Shu J, Zhao Z, Sun Z, Luo B: Sequence analysis of EBV immune evasion gene BNLFL2a in EBV associated tumors and healthy individuals from nasopharyngeal carcinoma endemic regions of China. J Med Virol. 2015, 87:1946-1952. 10.1002/jmv.24254

24. Shinosaki-Ushiku A, Kunita A, Isogai M, Hibiya T, Ushiku T, Takada K, Fukayama M: Profiling of virus-encoded microRNAs in Epstein-Barr virus-associated gastric carcinoma and their roles in gastric carcinogenesis. J Virol. 2015, 89:5581-5591. 10.1128/JVI.03699-14

25. Sivachandran N, Dawson CW, Young LS, Liu FF, Middeldorp J, Frappier L: Contributions of the Epstein-Barr virus EBNA1 protein to gastric carcinogenesis. J Virol. 2015, 89:10110-10114. 10.1128/JVI.01110-15

26. Sundar R, Qamra A, Keng Tan AL, et al.: Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer. 2018, 21:1064-1070. 10.1007/s10120-018-0851-9

27. Wang A, Zhang W, Lin M, Zhang J, Li S, Tong F, Zhou Y: Differential expression of EBV proteins LMP1 and BHRF1 in EBV-associated gastric and nasopharyngeal cancer tissues. Mol Med Rep. 2016, 13:4151-4158. 10.3892/mmr.2016.5007

28. Wang X, Liu X, Jia Y, Chao Y, Xing X, Wang Y, Luo B: Widespread sequence variation in the Epstein-Barr virus latent membrane protein 2A gene among Northern Chinese isolates. J Gen Virol. 2010, 91:2564-2573. 10.1099/vir.0.021881-0

29. Wang X, Wu G, Wang Y, Sun Z, Luo B: Gene variations of Epstein-Barr virus nuclear antigen 5A in nasopharyngeal carcinomas, gastric carcinomas and healthy carriers in northern China. Arch Virol. 2015, 158:2041-2048. 10.1007/s00705-015-1702-y

30. Kawaoe A, Kawai T, Kuboki Y, et al.: Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017, 20:407-415. 10.1007/s10120-016-0651-3

31. Warnimonts S, Thitivanchiipong P, Keelawat S, Mutirangura A, Kitkumthorn N: Distribution of the Epstein-Barr virus in the normal stomach and gastric lesions in Thai population. J Med Virol. 2019, 91:444-449. 10.1002/jmv.25318

32. Wu G, Wang Y, Chao Y, Jia Y, Zhao C, Luo B: Characterization of Epstein-Barr virus type 1 nuclear antigen
3C sequence patterns of nasopharyngeal and gastric carcinomas in northern China. Arch Virol. 2012, 157:845-853. 10.1007/s00705-012-1241-y

34. Liu Y, Yang W, Pan Y, Ji J, Lu Z, Ke Y: Genome-wide analysis of Epstein-Barr virus (EBV) isolated from EBV-associated gastric carcinoma (EBVaGC). Oncotarget. 2016, 7:4903-4914. 10.18632/oncotarget.6751

35. Zhang Y, Zhao XX, Tan C, et al.: Epstein-Barr virus latent membrane protein 2A suppresses the expression of HER2 via a pathway involving TWIST and YB-1 in Epstein-Barr virus-associated gastric carcinomas. Oncotarget. 2015, 6:207-220. 10.18632/oncotarget.2702

36. Zhao J, Liang Q, Cheung KF, et al.: Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells. Cancer. 2015, 119:304-312. 10.1002/cncr.27724